Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou, 450052, Henan, China.
Department of Oncology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, Henan, China.
J Transl Med. 2023 Nov 1;21(1):774. doi: 10.1186/s12967-023-04651-0.
The phosphoinositide 3-kinase (PI3K)/AKT signaling pathway plays a crucial role in the pathogenesis of cancer. The dysregulation of this pathway has been linked to the development and initiation of various types of cancer. Recently, epigenetic modifications, particularly N6-methyladenosine (m6A), have been recognized as essential contributors to mRNA-related biological processes and translation. The abnormal expression of m6A modification enzymes has been associated with oncogenesis, tumor progression, and drug resistance. Here, we review the role of m6A modification in regulating the PI3K/AKT pathway in cancer and its implications in the development of novel strategies for cancer treatment.
磷酸肌醇 3-激酶 (PI3K)/AKT 信号通路在癌症的发病机制中起着至关重要的作用。该通路的失调与各种类型癌症的发生和起始有关。最近,表观遗传修饰,特别是 N6-甲基腺苷 (m6A),已被认为是与 mRNA 相关的生物学过程和翻译有关的重要因素。m6A 修饰酶的异常表达与致癌、肿瘤进展和耐药性有关。在这里,我们综述了 m6A 修饰在调节癌症中 PI3K/AKT 通路中的作用及其在癌症治疗新策略开发中的意义。